• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

阿仑膦酸钠在缓解围绝经期骨丢失中的作用：一项双盲随机对照初步研究。

The role of alendronate in mitigating perimenopausal bone loss: a double-blind randomized controlled pilot study.

机构信息

Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Francisco, California, USA.

出版信息

Fertil Steril. 2010 Aug;94(3):1138-40. doi: 10.1016/j.fertnstert.2009.11.030. Epub 2010 Jan 8.

DOI:10.1016/j.fertnstert.2009.11.030
PMID:20056199
Abstract

Compared with placebo, alendronate treatment resulted in a significant protection against bone loss in healthy perimenopausal women. This protection occurred at both the spine and the hip and was evident after 6 months of therapy.

摘要

与安慰剂相比，阿伦膦酸钠治疗可显著预防健康绝经前妇女的骨质流失。这种保护作用发生在脊柱和臀部，并且在治疗 6 个月后就很明显。

相似文献

1
The role of alendronate in mitigating perimenopausal bone loss: a double-blind randomized controlled pilot study.阿仑膦酸钠在缓解围绝经期骨丢失中的作用：一项双盲随机对照初步研究。
Fertil Steril. 2010 Aug;94(3):1138-40. doi: 10.1016/j.fertnstert.2009.11.030. Epub 2010 Jan 8.
2
Response rate of bone mineral density to teriparatide in postmenopausal women with osteoporosis.绝经后骨质疏松症女性骨矿物质密度对特立帕肽的反应率
Bone. 2006 Dec;39(6):1268-75. doi: 10.1016/j.bone.2006.06.007. Epub 2006 Aug 1.
3
Treatment with alendronate plus calcium, alendronate alone, or calcium alone for postmenopausal low bone mineral density.阿仑膦酸钠联合钙剂、单用阿仑膦酸钠或单用钙剂治疗绝经后低骨密度。
Curr Med Res Opin. 2007 Jun;23(6):1341-9. doi: 10.1185/030079907X188035.
4
Denosumab in postmenopausal women with low bone mineral density.地诺单抗用于绝经后低骨密度女性。
N Engl J Med. 2006 Feb 23;354(8):821-31. doi: 10.1056/NEJMoa044459.
5
Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (Efficacy of FOSAMAX versus EVISTA Comparison Trial) International.阿仑膦酸钠对骨密度低的绝经后女性的骨密度和骨转换的影响大于雷洛昔芬：国际EFFECT（福善美与易维特比较试验的疗效）研究结果。
J Intern Med. 2004 Apr;255(4):503-11. doi: 10.1111/j.1365-2796.2004.01317.x.
6
Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.静脉注射5毫克唑来膦酸治疗既往接受阿仑膦酸钠治疗的绝经后低骨密度女性。
Bone. 2007 Jul;41(1):122-8. doi: 10.1016/j.bone.2007.03.011. Epub 2007 Mar 24.
7
[Alendronate in postmenopausal women with osteopenia and osteoporosis: effects on bone mineral density during treatment and after withdrawal].[阿仑膦酸钠对绝经后骨质减少和骨质疏松症女性的影响：治疗期间及停药后的骨密度变化]
Zhonghua Yi Xue Za Zhi. 2002 Sep 25;82(18):1254-6.
8
Alendronate prevents loss of bone density associated with discontinuation of hormone replacement therapy: a randomized controlled trial.阿仑膦酸盐可预防与激素替代疗法停用相关的骨密度丢失：一项随机对照试验。
Arch Intern Med. 2003 Apr 14;163(7):789-94. doi: 10.1001/archinte.163.7.789.
9
A double-blinded head-to-head trial of minodronate and alendronate in women with postmenopausal osteoporosis.米诺膦酸盐与阿仑膦酸盐治疗绝经后骨质疏松症女性的双盲头对头试验。
Bone. 2009 Jun;44(6):1078-84. doi: 10.1016/j.bone.2009.02.016. Epub 2009 Mar 2.
10
Alendronate for osteoporosis. Safe and efficacious nonhormonal therapy.阿仑膦酸钠用于治疗骨质疏松症。安全有效的非激素疗法。
Can Fam Physician. 1998 Feb;44:327-32.

引用本文的文献

1
Bisphosphonates Preserve Bone Mineral Density and Suppress Bone Turnover Markers in Early Menopausal Women: A Systematic Review and Meta-Analysis of Randomized Trials.双膦酸盐可维持绝经早期女性的骨矿物质密度并抑制骨转换标志物：一项随机试验的系统评价和荟萃分析
JBMR Plus. 2023 Apr 14;7(6):e10748. doi: 10.1002/jbm4.10748. eCollection 2023 Jun.